Drug Profile
AAV hTERT
Alternative Names: AAV-hTERT; LGT; Libella Gene TherapyLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Libella Gene Therapeutics
- Class Anti-ischaemics; Antidementias; Gene therapies
- Mechanism of Action Gene transference; Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Chronic limb-threatening ischemia
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease in Colombia (Intrathecal, Injection)
- 28 Nov 2022 No recent reports of development identified for phase-I development in Alzheimer's-disease in Colombia (IV, Injection)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Chronic limb threatening ischemia (In the elderly, In adults) in Colombia (IV)